Comparison of 200mg retarded release levodopa/carbidopa - With 150mg levodopa/carbidopa/entacapone application: Pharmacokinetics and efficacy in patients with Parkinson's disease

Journal of Neural Transmission

Volumn 114, Issue 11, 2007, Pages 1457-1462

  Muller T ^a   Ander, L ^a   Kolf, K ^a   Woitalla, D ^a   Muhlack, S ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Entacapone; Levodopa; Parkinson's disease; Retarded release

Indexed keywords

3 O METHYLDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA; 3-METHOXYTYROSINE; ANTIPARKINSON AGENT; CARBIDOPA; CATECHOL DERIVATIVE; DRUG DERIVATIVE; ENTACAPONE; NITRILE; TYROSINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED DRUG RELEASE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; TYROSINE;

EID: 36148978164     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-007-0773-x     Document Type: Article

References (18)

1. AF Arnsten BM Li 2005 Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions Biol Psychiatry 57 1377 1384
2. G Block C Liss S Reines J Irr D Nibbelink 1997 Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group Eur Neurol 37 23 27
3. G Fabbrini JL Juncos MM Mouradian C Serrati TN Chase 1987 3-O-methyldopa and motor fluctuations in Parkinson's disease Neurology 37 856 859
4. S Fahn D Oakes I Shoulson K Kieburtz A Rudolph A Lang CW Olanow C Tanner K Marek 2004 Levodopa and the progression of Parkinson's disease N Engl J Med 351 2498 2508
5. MJ Frank 2005 Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism J Cogn Neurosci 17 51 72
6. M Ghilardi C Ghez V Dhawan J Moeller M Mentis T Nakamura A Antonini D Eidelberg 2000 Patterns of regional brain activation associated with different forms of motor learning Brain Res 871 127 145
7. CG Goetz PA LeWitt M Weidenman 2003 Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program Mov Disord 18 1455 1458
8. WC Koller JT Hutton E Tolosa R Capilldeo 1999 Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group Neurology 53 1012 1019
9. T Müller S Benz H Przuntek 2002 Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients Can J Neurol Sci 29 73 77
10. T Müller C Erdmann D Bremen WE Schmidt S Muhlack D Woitalla O Goetze 2006a Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients Clin Neuropharmacol 29 61 67
11. T Müller C Erdmann S Muhlack D Bremen H Przuntek O Goetze D Woitalla 2006b Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease J Neural Transm 113 1441 1448
12. T Müller W Kuhn T Schulte H Przuntek 2003 Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease Neurosci Lett 339 25 28
13. T Müller S Schafer W Kuhn H Przuntek 2000 Correlation between tapping and inserting of pegs in Parkinson's disease Can J Neurol Sci 27 311 315
14. T Nakamura MF Ghilardi M Mentis V Dhawan M Fukuda A Hacking JR Moeller C Ghez D Eidelberg 2001 Functional networks in motor sequence learning: abnormal topographies in Parkinson's disease Hum Brain Mapp 12 42 60
15. A Nieoullon A Coquerel 2003 Dopamine: a key regulator to adapt action, emotion, motivation and cognition Curr Opin Neurol 16 Suppl 2 S3 S9
16. JG Nutt 2000 Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 55 S33 S37
17. P Soares-da-Silva A Parada P Serrao 2000 The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase Brain Res 863 293 297
18. J Uekermann I Daum S Peters B Wiebel H Przuntek T Müller 2003 Depressed mood and executive dysfunction in early Parkinson's disease Acta Neurol Scand 107 341 348